Literature DB >> 6613213

[Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis].

R Seitz, W Schwerk, R Arnold.   

Abstract

A 76 years-old male patient received mebendazole, 500 mg four times a day (appr. 29 mg per kg body weight) for treatment of sonographically and serologically proven cystic echinococcosis of the liver. On day 49 of this therapy he developed an exanthema, and mebendazole-administration was interrupted. At the same time a striking rise of serum transaminases was observed. When enzyme levels normalized, a reexposure using a low dose of mebendazole lead to a new more pronounced rise of transaminases suggesting a drug-induced hepatocellular damage. No measurable change of the Echinococcus cyst was observed during treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6613213

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  3 in total

Review 1.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

2.  Cytotoxicity of mebendazole against established cell lines from the human, rat, and mouse liver.

Authors:  F Higa; K Kitsukawa; M Gaja; M Tateyama; K Shikiya; Y Shigeno; F Kinjo; A Saito
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

3.  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.

Authors:  Jong-Yil Chai; Bong-Kwang Jung; Sung-Jong Hong
Journal:  Korean J Parasitol       Date:  2021-06-21       Impact factor: 1.341

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.